Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR− Trial

Authors :: Graeser, Monika
Gluz, Oleg
Biehl, Claudia
Ulbrich-Gebauer, Daniel
Christgen, Matthias
Palatty, Jenci
Kuemmel, Sherko
Grischke, Eva-Maria
Augustin, Doris
Braun, Michael
Potenberg, Jochem
Wuerstlein, Rachel
Krauss, Katja
Schumacher, Claudia
Forstbauer, Helmut
Reimer, Toralf
Stefek, Andrea
Fischer, Hans Holger
Pelz, Enrico
Zu Eulenburg, Christine
Kates, Ronald
Ni, Hua
Kolberg-Liedtke, Cornelia
Feuerhake, Friedrich
Kreipe, Hans Heinrich
Nitz, Ulrike
Harbeck, Nadia
WSG-ADAPT Investigators
Source :: Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587
Publication Year :: 2023
Publisher :: RWTH Aachen University, 2023.
Abstract: Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587<br />Published by AACR, Philadelphia, Pa. [u.a.]

Language :: English
ISSN :: 10780432
Database :: OpenAIRE
Journal :: Clinical cancer research 29(4), 805-814 (2023). doi:10.1158/1078-0432.CCR-22-1587
Accession number :: edsair.doi.dedup.....5406cbc071dedb40848014af69449e85
Full Text :: https://doi.org/10.18154/rwth-conv-250791

Full Text Access

Tools